China’s Hangzhou Chance Pharmaceuticals Co., Ltd., a specialist in lung drug delivery, has entered into a partnership with fellow Chinese firm Yiling Pharmaceutical Co., Ltd (SHE: 002603). The collaboration aims to leverage Hangzhou Chance’s experience and technology in the development of inhalation powder mist agents, thereby facilitating Yiling Pharma in the development of novel drug molecules. The financial details of this strategic alliance have not been disclosed.
Leveraging Expertise in Inhalation Powder Technology
Hangzhou Chance Pharmaceuticals brings to the table its expertise in the development of inhalation powder mist agents, a critical area in the delivery of lung medications. This technology is poised to enhance the efficacy and convenience of drug administration, particularly for patients with respiratory conditions.
Supporting Yiling Pharmaceutical’s Drug Development Endeavors
Yiling Pharmaceutical Co., Ltd will benefit from Hangzhou Chance’s technological prowess as it pursues the development of innovative drug molecules. The partnership is expected to accelerate the process of bringing new treatments to market, improving patient outcomes and expanding therapeutic options.-Fineline Info & Tech
Leave a Reply